Showing 7,441 - 7,460 results of 18,470 for search 'significantly ((((((lower decrease) OR (teer decrease))) OR (a decrease))) OR (linear decrease))', query time: 0.77s Refine Results
  1. 7441
  2. 7442

    <b>Metabolic Improvements with Tirzepatide in Lipodystrophy: A Novel Option?</b> by Rasimcan Meral (5022425)

    Published 2025
    “…These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy, GL) or partial (partial lipodystrophy, PL; e.g. familial partial lipodystrophy, FPLD) absence of adipocyte mass leading to a decreased ability to store lipids safely. Excess lipids are more likely to be stored in non-adipose tissues, which leads to the metabolic manifestations. …”
  3. 7443

    Life Cycle Environmental Impacts of Sewage Sludge Pyrolysis and Their Dynamic Evolution by Jan Matuštík (22500291)

    Published 2025
    “…The dynamic analysis demonstrates that the system provides significant temporal carbon capture, which gradually decreases as biochar decomposes in soil. …”
  4. 7444
  5. 7445

    Mean cocaine consumed (mg/kg) over 10 days. by Christopher Rowan (21499924)

    Published 2025
    “…<div><p>Background</p><p>Cocaine abuse and Cocaine Use Disorder (CUD) is an increasingly urgent public health issue leading to major health risks often resulting in a decreased lifespan and quality of life. Previous human research has described brain function of cocaine addicts however the amount of cocaine use, duration of use, and exclusion of using other drugs (i.e., nicotine and alcohol) have all been difficult to control. …”
  6. 7446

    Demographic information. by Aisha Ali Hawsawi (20685883)

    Published 2025
    “…<div><p>Background and aims</p><p>In recent years, increased awareness of the psychological wellbeing of healthcare professionals and students has become a pressing public health issue affecting care delivery. …”
  7. 7447
  8. 7448
  9. 7449
  10. 7450
  11. 7451

    Supplementary Material for: Non-Prescribed Use of Opioid Agonist Medications and Associations with Non-Fatal Overdoses: A Repeated Cross-Sectional Study Across a Decade of Reduced... by figshare admin karger (2628495)

    Published 2025
    “…Introduction: Non-prescribed use of opioid agonist treatment (OAT) medications is a public health concern. This study analyses the prevalence of non-prescribed use and non-fatal overdoses in Norway in 2013 and 2023, a period marked by an increasingly flexible OAT regimen, and examines associations between non-prescribed use and non-fatal overdoses. …”
  12. 7452
  13. 7453

    Assessment of left ventricular (LV) remodeling 2 weeks after transverse aortic constriction (TAC) in male mice. by Zhen Zhou (184390)

    Published 2025
    “…<p><b>(A)</b> Representative images of LV contraction measurement from short-axis parasternal view using M-mode. …”
  14. 7454

    Data Sheet 1_Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized control... by Sumaiah J. Alarfaj (12889115)

    Published 2025
    “…</p>Results<p>Compared to the placebo group (n = 24), the atorvastatin group (n = 23) exhibited a significant decrease in the level of IL-6 (p = 0.001), S1P (p = 0.0001), TNF-α (p = 0.003), NO (p = 0.0001), CRP (p = 0.015), ESR (p = 0.012), PMS (p = 0.013), and fecal calprotectin (p = 0.0003), and improved SF-36 (p = 0.006). …”
  15. 7455
  16. 7456
  17. 7457
  18. 7458

    Data_Sheet_1_A randomized double-blinded study assessing the effect of different doses of transnasal dexmedetomidine on the median effective concentration of ropivacaine for a caud... by Fu Wang (10556)

    Published 2024
    “…</p>Conclusion<p>IN-DEX decreased the EC50 of ropivacaine for the caudal block, and there was a specific dose-dependent effect for IN-DEX. …”
  19. 7459

    Image 2_A unique polygenic mouse model of obesity exhibits a distinct immunological profile that may offer protection against systemic inflammation, diabetes, and behavioral impair... by Ulrike Gimsa (9730208)

    Published 2025
    “…The DU6 polygenic mouse line was selected over more than 180 generations for a high body mass. Unlike other mouse lines, DU6 mice do not develop diabetes despite significant obesity. …”
  20. 7460

    Table 2_A unique polygenic mouse model of obesity exhibits a distinct immunological profile that may offer protection against systemic inflammation, diabetes, and behavioral impair... by Ulrike Gimsa (9730208)

    Published 2025
    “…The DU6 polygenic mouse line was selected over more than 180 generations for a high body mass. Unlike other mouse lines, DU6 mice do not develop diabetes despite significant obesity. …”